Léim ar aghaidh chuig an bpríomhábhar
Gnáthamharc

Medicinal Products

Dáil Éireann Debate, Wednesday - 18 January 2023

Wednesday, 18 January 2023

Ceisteanna (1695)

Pa Daly

Ceist:

1695. Deputy Pa Daly asked the Minister for Health his views on the availability of concerta methylphenidate in Ireland. [2245/23]

Amharc ar fhreagra

Freagraí scríofa

Janssen, the marketing authorisation holder for Concerta products, has informed the Health Products Regulatory Authorithy (HPRA) that it is encountering intermittent supply shortages of various strengths of Concerta, which is impacting countries in multiple regions. This is due to global supply chain issues related to component availability and increased demand in multiple markets.

The company has stated that there are allocations in place to ensure equitable distribution to mitigate the impact on patients in Ireland. The company has also stated that it is working closely with pharmacies to ensure patients receive their medications, and if there are any localised supply issues, pharmacies can contact Janssen so that the required quantity can be released for the patient.

Barr
Roinn